Connect with us

Press Releases

Okayama University research: A novel 3D cell culture model sheds light on the mechanisms driving fibrosis in pancreatic cancer

OKAYAMA, Japan, Aug. 28, 2020 /PRNewswire/ — In a recent study published in Biomaterials, researchers at Okayama University created a new 3D cell culture model of pancreatic cancer that closely mimics the “fibrotic” tissue characteristically observed in patients. Pancreatic cancer is a…

Avatar

Published

on

OKAYAMA, Japan, Aug. 28, 2020 /PRNewswire/ — In a recent study published in Biomaterials, researchers at Okayama University created a new 3D cell culture model of pancreatic cancer that closely mimics the “fibrotic” tissue characteristically observed in patients.

Pancreatic cancer is a lethal condition with a very poor prognosis—only ~9% of patients live to see another 5 years after diagnosis. A prime feature of pancreatic cancer is the presence of fibrotic tissue within the tumors. This fibrotic tissue is akin to the scarring that surrounds a wound. Fibrotic tissue entraps the cancer cells within it, making it difficult to therapeutically target these cells. Thus, understanding the mechanisms behind fibrotic tissue development is imperative for creating effective treatment strategies. Professor Mitsunobu R. Kano and Assistant Professor Hiroyoshi Y. Tanaka from Okayama University and colleagues have now created a three-dimensional (3D) cell culture model of pancreatic cancer in the laboratory which closely replicate the fibrotic nature of the tumors.

Fibrotic tissue develops when cancer cells and specialized cells called fibroblasts closely interact with each other. The patterns of fibrotic tissue seen in pancreatic cancer vary greatly from patient to patient. The researchers started by analyzing patient tumor samples and found that fibrotic tissue took up as little as 40% and as much as 80% of the space within tumors. For the 3D cell culture model to truly mimic the cancer, it would need to reflect this wide range in the amount of fibrotic tissue observed. To achieve this, the team tried seeding pancreatic cancer cells and fibroblasts at different ratios. Indeed, by trying various ratios, the team could create 3D pancreatic cancer tissues with any given amount of fibrotic tissue—most importantly within the clinically observed range.

The fibroblasts within these models were subsequently scrutinized to unravel cellular changes driving fibrotic tissue development. It was found that two proteins, namely, SMAD2/3 and YAP were the driving force behind such changes. These two proteins, however, did not act alone: the combined activity of SMAD2/3 and YAP were necessary for the fibroblasts to acquire the abnormal characteristics seen in tumor tissue. A host of cellular signaling systems were in place to enable the function of SMAD2/3 and YAP—some of these systems were common while others were unique to each protein.

Cell culture models of pancreatic cancer play an indispensable part in understanding the disease since they allow mechanistic analyses at a detail that would otherwise be difficult to achieve in studies using laboratory animals or clinical specimens. However, cell culture models to date generally failed to recreate the characteristic, densely fibrotic tissue observed in pancreatic cancer, much less the variability observed between patients. The 3D cell culture model of pancreatic cancer developed in this study overcomes these issues. The new model may enable researchers to understand the differences between tumors showing various degrees of fibrosis and potentially customize strategies to target them. “Our novel model will be useful in promoting the understanding of the complex mechanisms by which the fibrotic stroma develops and how it might be therapeutically targeted”, conclude the researchers.

Background

Pancreatic cancer and fibrotic tissue: Pancreatic cancer is one of the most difficult to treat cancers. This is in large part due to the dense, fibrotic tissue present within the tumor.

Fibrosis is a biological process that occurs in damaged internal organs (such as the pancreas) when wound healing mechanisms go awry. Although fibrosis initiates as a process that protects a damaged organ, it sometimes also ends up creating an environment that promotes the growth of cancer cells. Thus, fibrotic tissue is closely associated with the presence and spread of pancreatic cancer. Fibrotic tissue also facilitates drug resistance thereby preventing the cancer cells from responding to any medication. Fibrotic tissue is therefore a huge barrier to understanding the complexities of pancreatic cancer and developing therapeutic strategies.

Link to figure

https://www.okayama-u.ac.jp/up_load_files/research_highlights/113_image_1.jpg

Caption

Pancreatic cancer cells (green areas) and fibroblasts (non-green areas) were mixed in specialized culture vessels to create a novel three-dimensional cell culture model of pancreatic cancer in the laboratory. The cells were mixed at various ratios to enable the tweaking of the amount of fibrosis, from almost no fibrotic tissue (bottom panel, leftmost image) to almost completely fibrotic tissue (bottom panel, 2nd image from the left). When cultured together with cancer cells, fibroblasts began to express a protein characteristic of cancer tissue (red) that was not observed when fibroblasts were cultured alone (bottom panel, left most image). The model thus successfully captures and allows the analysis of the interactions between cancer cells and fibroblasts that drive the formation of fibrotic tissue.

Reference

Hiroyoshi Y. Tanaka, Tsuyoshi Kurihara, Takuya Nakazawa, Michiya Matsusaki, Atsushi Masamune, Mitsunobu R. Kano. Heterotypic 3D pancreatic cancer model with tunable proportion of fibrotic elements. Biomaterials, 251, August 2020, 120077.

DOI : 10.1016/j.biomaterials.2020.120077

https://www.sciencedirect.com/science/article/pii/S0142961220303239

Reference (Okayama Univ. e-Bulletin): Professor KANO’s team

OU-MRU Vol.62:3D tissue model offers insights into treating pancreatic cancer

Further information

Okayama University

1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan

Public Relations Division

E-mail: [email protected]

Website: http://www.okayama-u.ac.jp/index_e.html

Okayama Univ. e-Bulletin: http://www.okayama-u.ac.jp/user/kouhou/ebulletin/

Okayama University Medical Research Updates OU-MRU

Archive of all volumes:

https://www.okayama-u.ac.jp/eng/research/ou-mru.html

Vol.1:Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testing

Vol.79:Novel blood-based markers to detect Alzheimer’s disease

About Okayama University

Okayama University is one of the largest comprehensive universities in Japan with roots going back to the Medical Training Place sponsored by the Lord of Okayama and established in 1870. Now with 1,300 faculty and 13,000 students, the University offers courses in specialties ranging from medicine and pharmacy to humanities and physical sciences.

Okayama University is located in the heart of Japan approximately 3 hours west of Tokyo by Shinkansen.

SOURCE Okayama University

Source: https://www.prnewswire.com:443/news-releases/okayama-university-research-a-novel-3d-cell-culture-model-sheds-light-on-the-mechanisms-driving-fibrosis-in-pancreatic-cancer-301120271.html

Press Releases

Jubilant Therapeutics kündigt Präsentation auf virtueller ASH-Jahrestagung 2020 an

BEDMINSTER, N. J., 25. November 2020 /PRNewswire/ — Jubilant Therapeutics Inc., ein Biopharma-Unternehmen, das kleine Molekülmodulatoren entwickelt, um medizinische Bedürfnisse in der Onkologie und bei Autoimmunkrankheiten zu erfüllen, hat heute bekannt gegeben, dass eine Kurzdarstellung…

Avatar

Published

on

BEDMINSTER, N. J., 25. November 2020 /PRNewswire/ — Jubilant Therapeutics Inc., ein Biopharma-Unternehmen, das kleine Molekülmodulatoren entwickelt, um medizinische Bedürfnisse in der Onkologie und bei Autoimmunkrankheiten zu erfüllen, hat heute bekannt gegeben, dass eine Kurzdarstellung zu seinem LSD1/HDAC6-Doppelhemmer JBI-802 zur Präsentation auf der 62. Jahrestagung der American Society of Hematology (ASH), die von 5. bis 8. Dezember 2020 in virtueller Form stattfindet, zugelassen wurde.

„Wir freuen uns darauf, auf der virtuellen ASH-Jahrestagung 2020 über unseren neuartigen wirksamen und selektiven LSD1/HDAC6-Doppelhemmer für die Krebsbehandlung zu sprechen”, erklärte Syed Kazmi, Präsident und Chief Executive Officer von Jubilant Therapeutics. „Unsere Arbeit, JBI-802 als potenzielles, differenziertes Therapeutikum für die Behandlung ausgewählter hämatologischer und solider Tumoren mit spezifischen Gensignaturen in die klinische Praxis zu bringen, schreitet voran, und wir gehen davon aus, dass wir in der zweiten Hälfte des nächsten Jahres erste Studien am Menschen einleiten können.”

Die Kurzdarstellung ist derzeit auf der ASH-Konferenz-Website verfügbar und lautet folgendermaßen:

Titel: Novel Dual Inhibitor of LSD1-HDAC6/8 for Treatment of Cancer (dt. Neuartiger LSD1-HDAC6/8-Doppelhemmer zur Behandlung von Krebs)

Datum: Montag, 7. Dezember 2020

Session: 802. Chemical Biology and Experimental Therapeutics: Poster III (Chemische Biologie und experimentelle Therapeutika: Poster III)

Kurzdarstellung: 3378

Vortragende(r): Dhanalakshmi Sivanandhan, Ph.D., stellvertretender Vizepräsident und Leiter Biologie bei Jubilant Therapeutics Inc.

Informationen zu Jubilant Therapeutics 

Jubilant Therapeutics Inc. ist ein patientenorientiertes biopharmazeutisches Unternehmen, das wirksame und selektive kleine Molekülmodulatoren entwickelt, um medizinische Bedürfnisse in der Onkologie und bei Autoimmunerkrankungen zu erfüllen. Seine fortschrittliche Forschungsstrategie integriert strukturbasiertes Design und Berechnungsalgorithmen, um neuartige, präzise Therapeutika zu entdecken und zu entwickeln, die sowohl gegen erste Ziele ihrer Art als auch gegen validierte, aber hartnäckige Ziele in genetisch definierten Patientenpopulationen gerichtet sind. Die unternehmerisch denkende Führung und die wissenschaftlichen Teams des Unternehmens streben nach Schnelligkeit und Effizienz, indem sie ein Geschäftsmodell anwenden, das die bewährten und synergetischen Fähigkeiten der Wertschöpfungskette und der gemeinsamen Dienstleistungen von Jubilant Life Sciences Limited nutzt. Jubilant Therapeutics hat seinen Hauptsitz in den USA und wird von weltweit anerkannten Meinungsführern und Mitgliedern des Wissenschaftlichen Beirats geleitet. Weitere Information finden Sie auf www.jubilanttx.com oder folgen Sie uns auf Twitter @JubilantTx oder LinkedIn.

Logo: https://mma.prnewswire.com/media/1064788/Jubilant_Therapeutics_Logo.jpg

SOURCE Jubilant Therapeutics Inc.

Source: https://www.prnewswire.com:443/news-releases/jubilant-therapeutics-kundigt-prasentation-auf-virtueller-ash-jahrestagung-2020-an-825840214.html

Continue Reading

Press Releases

ROSEN, A TOP RANKED LAW FIRM, Reminds Raytheon Technologies Corporation f/k/a Raytheon Company Investors of Important Deadline in Securities Class Action First Filed by the Firm; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RTX, RTN

NEW YORK, Nov. 24, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Raytheon Technologies Corporation f/k/a Raytheon Company (NYSE: RTX, RTN) between February 10, 2016 and October 27, 2020, inclusive (the “Class Period”), of…

Avatar

Published

on

NEW YORK, Nov. 24, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Raytheon Technologies Corporation f/k/a Raytheon Company (NYSE: RTX, RTN) between February 10, 2016 and October 27, 2020, inclusive (the “Class Period”), of the important December 29, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Raytheon investors under the federal securities laws.

To join the Raytheon class action, go to http://www.rosenlegal.com/cases-register-1975.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Raytheon had inadequate disclosure controls and procedures and internal control over financial reporting; (2) Raytheon had faulty financial accounting; (3) as a result, Raytheon misreported its costs regarding Raytheon’s Missiles & Defense business since 2009; (4) as a result of the foregoing, Raytheon was at risk of increased scrutiny from the government; (5) as a result of the foregoing, Raytheon would face a criminal investigation by the U.S. Department of Justice (“DOJ”); and (6) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1975.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY  10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

SOURCE Rosen Law Firm, P.A.

Related Links

www.rosenlegal.com

Source: https://www.prnewswire.com:443/news-releases/rosen-a-top-ranked-law-firm-reminds-raytheon-technologies-corporation-fka-raytheon-company-investors-of-important-deadline-in-securities-class-action-first-filed-by-the-firm-encourages-investors-with-losses-in-excess-of-100k-301180237.html

Continue Reading

Press Releases

SHIELD annonce DeviceSHIELD pour protéger les petites entreprises contre la cyberfraude pendant la pandémie de COVID-19

DeviceSHIELD fournira gratuitement des renseignements sur les risques à 90 % des entreprises en ligne pour aider à lutter contre la fraude et à prévenir des pertes financières moyennes de 200 000 $ en raison de cyberattaques¹ MENLO PARK, Californie, 25 novembre 2020 /PRNewswire/ –…

Avatar

Published

on

DeviceSHIELD fournira gratuitement des renseignements sur les risques à 90 % des entreprises en ligne pour aider à lutter contre la fraude et à prévenir des pertes financières moyennes de 200 000 $ en raison de cyberattaques¹ 

MENLO PARK, Californie, 25 novembre 2020 /PRNewswire/ — SHIELD, la plus importante entreprise de cybersécurité au monde spécialisée dans la cyberfraude et la vérification de l’identité, a lancé aujourd’hui DeviceSHIELD. Il s’agit d’une solution contre la cyberfraude conçue spécialement pour lutter contre l’augmentation des attaques frauduleuses à l’encontre des entreprises en ligne pendant la pandémie de COVID-19. La solution fournit des renseignements utiles en temps réel pour repérer les faux dispositifs et protéger les entreprises contre les fraudeurs, les atteintes à la réputation et les transactions frauduleuses.

Pendant la pandémie de COVID-19, la cyberfraude est devenue l’activité criminelle qui connaît la croissance la plus rapide, ce qui expose les entreprises et les consommateurs à des risques accrus. Aujourd’hui, les consommateurs effectuent davantage de transactions numériques et utilisent de plus en plus d’applications en ligne. SHIELD a cerné plusieurs secteurs clés plus touchés par la cyberfraude depuis le début de la pandémie de COVID-19. Notamment les services à la demande comme la livraison de nourriture et la réservation de voiture avec chauffeur, le commerce électronique et les plateformes de marché, les jeux en ligne, les porte-monnaie électroniques, la fidélisation et les offres de « cashback », les services bancaires en ligne et le divertissement.

Au cours de la dernière année, les outils qu’utilisent les pirates informatiques se sont également perfectionnés. Les fraudeurs utilisent maintenant des émulateurs, des cloneurs d’applications, des réseaux privés virtuels et des systèmes de spoofing du système de positionnement mondial (GPS) des appareils mobiles pour commettre des fraudes.

« Plus il y a de transactions en ligne, plus les vulnérabilités à la cyberfraude sont importantes, et cela est plus que jamais d’actualité dans le contexte de la COVID-19, a déclaré Justin Lie, président-directeur général de SHIELD. Près de la moitié (43 %) des attaques en ligne visent maintenant les petites entreprises, et seulement 14 % d’entre elles sont activement prêtes à se défendre2. Nous avons créé une technologie pour protéger les secteurs en ligne qui, selon nous, sont les plus touchés par la COVID-19. Toutefois, toutes les entreprises qui comptent moins de 100 000 utilisateurs actifs par mois la recevront gratuitement, ce qui équivaut à environ 90 % de toutes les entreprises en ligne. »

SHIELD s’est engagé à lutter contre les répercussions économiques découlant de la pandémie de COVID-19. Le nombre de fraudeurs qui dissimulent l’identité en ligne de leurs appareils a augmenté à un rythme inattendu pendant la pandémie, ce qui rend les petites et moyennes entreprises particulièrement vulnérables. Les solutions conventionnelles de lutte contre la cyberfraude ont tendance à n’analyser que les attributs de surface et sont particulièrement inefficaces avec les appareils mobiles, ne permettant pas d’éliminer les menaces les plus subtiles et les plus furtives.

DeviceSHIELD est actuellement la seule technologie qui utilise l’ADN d’un dispositif pour identifier les utilisateurs malveillants, ce qui lui permet de détecter les fraudes avec une précision et une cohérence inégalées. Déployé en quelques minutes, DeviceSHIELD analyse des milliers d’attributs pour identifier un appareil, peu importe le nombre de fois dont il change son apparence, et indique exactement quels outils malveillants sont utilisés. La solution possède une fonction unique appelée SHIELD Sentinel qui lui permet de dresser continuellement le profil du risque tout au long d’une session utilisateur, une autre première dans le secteur. Elle s’appuie également sur le réseau de SHIELD, connu sous le nom de Global Intelligence Network, qui compte plus de sept milliards d’appareils et 500 millions d’utilisateurs sur six continents. Elle est donc en mesure de protéger un dispositif contre de nouveaux types inconnus de fraudes de manière proactive.

GGV Capital, Future Shape de Tony Fadell, Temasek, Wavemaker Partners et Tao Zhang sont des investisseurs de SHIELD. Les solutions de SHIELD sont actuellement utilisées par des entreprises mondiales comme Razer, Alibaba, Scalefast, Yamibuy, PayMaya et Sea Group pour lutter contre la cyberfraude.

À propos de SHIELD 

SHIELD est la première entreprise de cybersécurité au monde à se spécialiser dans les solutions de cyberfraude et de vérification d’identité. Les solutions de SHIELD vont de la prévention de la fraude à la sécurité du réseau, en passant par le renseignement sur le crédit et la vérification de l’identité. Possédant des bureaux dans le monde entier, SHIELD jouit de la confiance de superapplications, de plateformes de commerce électronique et de services de réservation de voiture avec chauffeur de premier plan partout dans le monde. Grâce à la reconnaissance des tendances et au profilage continu des risques, SHIELD fournit des renseignements utiles sur les dispositifs et des signaux en temps réel qui permettent aux entreprises d’évoluer en toute sécurité.

Pour en savoir plus, consultez le site https://shield.com/solutions/deviceshield.

Contact : 

Demande de renseignements des médias
Simone Jackenthal
Trident DMG
+ 1 (202) 923-5296
[email protected] 

1 Hiscox, « Hiscox Cyber Readiness Report 2019 (Rapport 2019 d’Hiscox sur la cyberpréparation) »
2
 CNBC, « Cyberattacks now cost companies $200,000 on average, putting many out of business (Les cyberattaques coûtent aujourd’hui 200 000 dollars en moyenne aux entreprises, ce qui en force beaucoup à mettre la clé sous la porte »

Logo – https://mma.prnewswire.com/media/1341295/SHIELD_tagline_Logo.jpg

Related Links

https://shield.com

SOURCE SHIELD

Source: https://www.prnewswire.com:443/news-releases/shield-annonce-deviceshield-pour-proteger-les-petites-entreprises-contre-la-cyberfraude-pendant-la-pandemie-de-covid-19-878635979.html

Continue Reading
Blockchain3 hours ago

The North American Bitcoin Conference Returns

Blockchain3 hours ago

12 Blockchain Industry Experts Offer Predictions For 2020

Blockchain3 hours ago

Bitcoin’s Halving May Not Pump Price Like Last Time – Here’s Why It Doesn’t Matter

Blockchain3 hours ago

What Are “Crypto/Digital Assets” and How Can They Be Taxed?

Blockchain3 hours ago

The Most Common Types Of Cryptocurrency Scams in 2020

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Venture Capital3 hours ago

Venture Capital3 hours ago

Venture Capital3 hours ago

Venture Capital3 hours ago

Venture Capital3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Startup3 hours ago

New Report Reveals Key Insights on the Future of Work in Latin America

Venture Capital3 hours ago

Ripple’s XRP surges 70% as Bitcoin craze sends investors flocking to smaller cryptocurrencies

Blockchain3 hours ago

Bison Trails launches QT protocol to help developers build on Libra

Blockchain3 hours ago

Stellar Lumens doubles in price following upgrade

Press Releases3 hours ago

Jubilant Therapeutics kündigt Präsentation auf virtueller ASH-Jahrestagung 2020 an

Startup3 hours ago

Mobile-only bank N26 launches N26 Smart, a new premium digital bank account for just €4.90 a month

Press Releases3 hours ago

ROSEN, A TOP RANKED LAW FIRM, Reminds Raytheon Technologies Corporation f/k/a Raytheon Company Investors of Important Deadline in Securities Class Action First Filed by the Firm; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RTX, RTN

Press Releases3 hours ago

SHIELD annonce DeviceSHIELD pour protéger les petites entreprises contre la cyberfraude pendant la pandémie de COVID-19

Press Releases3 hours ago

The “Haday Cup” 2020 Chinese Cuisine World Championship concludes in west China’s Chongqing Banan

Blockchain3 hours ago

Grayscale Bitcoin Trust (GBTC) Surges Past $10 Billion Assets Under Management

Trending